To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.

Part of paid clinical trials in New York, New York.

Sponsor
Pfizer
Study ID
NCT05576051
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • patterns of use of combination therapy and monotherapy — OTHER

Study Details

To estimate the efficacy of treatment with TNFi as monotherapy or combination therapy with MTX and compare and contrast efficacy with Tofacitinib as monotherapy and combination therapy in a real world setting.

Key Dates

Start date
Jun 4, 2015
Status verified
Dec 2025
Primary completion
Oct 7, 2015
Completion
Oct 7, 2015

Study Design

Enrollment
9,159 participants (actual)

Arms

  • Arm: All TNFi initiations
  • Arm: TNFi initiations after 11/6/2012 for comparisons with Tofacitinib initiators
  • Arm: RA patient in Corrona with initiation Tofacitinib during follow-up in Corron

Primary Outcome Measure

Clinical Disease Activity Index (CDAI) Score at 6 Months for Tofacitinib Monotherapy vs Tofacitinib With Methotrexate (MTX) [ Time Frame: At month 6 follow up visit ]

Locations (1)

FacilityCityStateZIPSite coordinators
PfizerNew YorkNew York10017-

Find similar trials in New York, NY

By condition
Rheumatoid arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
Pfizer· New York, NY

Related Studies